A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia

• Váldodahkkit: Sara Galimberti (Dahkki), Elisabetta Abruzzese (Dahkki), Giacomo Luci (Dahkki), Claudia Baratè (Dahkki), Luigia Luciano (Dahkki), Alessandra Iurlo (Dahkki), Giovanni Caocci (Dahkki), Riccardo Morganti (Dahkki), Fabio Stefanelli (Dahkki), Antonello Di Paolo (Dahkki)
• Materiálatiipa: Girji
• Almmustuhtton: MDPI AG, 2024-03-01T00:00:00Z.
• Fáttát: article
• Liŋkkat: Connect to this object online.

Ponatinib may be effective in chronic myeloid leukemia (CML) patients after failure of first/second line therapies. Although its efficacy for minimum plasma concentrations (C_min) is >21.3 ng/mL (equal to 40 nM), ponatinib may cause adverse events (AE) that require dose opti...